ClinicalTrials.gg
CompletedNCT04816175Updated Oct 13, 2022

Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay

An interventional study of Acquire Therapy in Microcephaly, Hyperkinesis With Developmental Delay and Global Developmental Delay, sponsored by Virginia Polytechnic Institute and State University. Completed at 1 site in United States. Open to participants aged 6 Months to 15 Years. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2019, registered Jan 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
6 Months to 15 Years
Sex
All
01

Study summary

This trial will consist of a clinical series of up to 50 children with Global Developmental Delay and concomitant microcephaly or hyperkinetic movements. All children will be assessed for psychomotor function using standardized assessments, goal specific assessments, with the potential addition of neuroimaging assessment, prior to and after receiving an intensive burst of neuromotor therapy. The interventional effects will be explored by comparing the pre and post interventional assessments and neuroimaging.

Read the detailed description

Up to 50 children between the ages of 6 months and 15 years will be recruited to participate in a burst of intensive neuromotor intervention in the form of Acquire therapy, delivered by the treatment team at Virginia Tech's Neuromotor Research Clinic. All children will have a diagnosis of Global Developmental Delay, with concomitant microcephaly or hyperkinetic movements. The children will be assessed for psychomotor function prior to and after the treatment intervention, using a series of standardized and goal specific assessments, with the possibility of additional neuroimaging assessments when possible. Acquire therapy is an intensive intervention in that it is delivered with high intensity, wherein goal directed behaviors are promoted at high levels of repetition and delivered at a high dose (4-6 hours a day) in an intensive burst of 3-4 weeks of 5 day a week treatment. Acquire therapy is an operant conditioning based intervention delivered in a cycle of refinement, reinforcement and repetition. It is play-based with activities selected to drive behavior toward goals that are specific to each child and selected based on each child's interests and needs. As such a specific protocol cannot be outlined. However, all goal directed activities are designed to promote awareness of and engagement with others and the environment.

02

Conditions studied

  • Microcephaly
  • Hyperkinesis With Developmental Delay
  • Global Developmental Delay

Keywords

  • Global Developmental Delay
  • Hyperkinesis
  • Microcephaly
  • Neurorehabilitation
  • Intensive Interventions
03

In context

Microcephaly

22 studies on the registry are indexed under Microcephaly; 5 are open to participants now.

Browse Microcephaly studies →

Lead sponsor

Virginia Polytechnic Institute and State University is the lead sponsor of 127 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Global Developmental Delay with Microcephaly or hyperkinetic movements.

Exclusion criteria

Exclusion Criteria:

  • Medical Instability
  • Under 6 months of age over 15 years of age
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Treatment Intervention

    All children will receive 3-5 weeks of intensive neuromotor Acquire therapy, an operant conditioning, play based therapy that maximizes therapeutic movements, attention, and engagement.

    Behavioral: Acquire Therapy

Interventions

  • BehavioralAcquire Therapy

    This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function

06

What researchers measure

Primary outcomes

  1. Change from baseline on Motor Function Assessment

    A validated motor function assessment tool the CanChild Gross Motor Function Measure -88 will be used to measure change on motor function. The child can score between 0 and 264 points. The higher the child's score the more tasks they were able to attempt and/or complete.

    Time frame: 5-12 weeks

Secondary outcomes

  1. Change from baseline on measure of EEG coherence in alpha band

    EEG data will be analyzed for changes in coherence in alpha band. Pre and post coherence in alpha band will be probed for changes by electrode pair.

    Time frame: 5-12 weeks

  2. Change from baseline on measure of EEG coherence in theta band.

    EEG data will be analyzed for changes in coherence in theta band. Pre and post coherence in theta band will be probed for changes by electrode pair.

    Time frame: 5-12 weeks

  3. Change from baseline on measure of EEG coherence in beta band.

    EEG data will be analyzed for changes in coherence in beta band. Pre and post coherence in beta band will be probed for changes by electrode pair.

    Time frame: 5-12 weeks

  4. Change from baseline on measure of EEG coherence in delta band.

    EEG data will be analyzed for changes in coherence in delta band. Pre and post coherence in delta band will be probed for changes by electrode pair.

    Time frame: 5-12 weeks

  5. Change from baseline on EEG power in alpha band.

    EEG data will be analyzed for changes in power in alpha band. Pre and post power will be compared for alpha band.

    Time frame: 5-12 weeks

  6. Change from baseline on EEG power in beta band.

    EEG data will be analyzed for changes in power in beta bands. Pre and post power will be compared for beta band.

    Time frame: 5-12 weeks

  7. Change from baseline on EEG power in theta band.

    EEG data will be analyzed for changes in power in theta band. Pre and post power will be compared for theta band.

    Time frame: 5-12 weeks

  8. Change from baseline on EEG power in delta bands.

    EEG data will be analyzed for changes in power in delta bands. Pre and post power will be compared for delta band.

    Time frame: 5-12 weeks

  9. Change from baseline on Disability Assessment

    Using the Pediatric evaluation of disability inventory with scores ranging from 0-100 with higher scored indicating greater functionality.

    Time frame: 5-12 weeks

  10. Change from baseline on fMRI measures of connectivity

    fMRI data will be probed for change from baseline on measures of connectivity.

    Time frame: 5-12 weeks

  11. Change from baseline on fMRI regional activation patterns.

    fMRI data will be probed for change from baseline on measures of regional activation.

    Time frame: 5-12 weeks

  12. Change from baseline on Motor Assessment

    Using the Peabody Developmental Motor Scales, the Peabody consists of 6 subtests, that are each completed according to the child's age as a starting point. If a child were to complete all 6 subtests, and were to start at the earliest age block for all subtests the child would complete 255 items, with scores ranging from 0-510, the higher the score the more tasks the child was able to complete.

    Time frame: 5-12 weeks

  13. Change from baseline on goal specific assessment

    Using a goal specific assessment form developed in the neuromotor research clinic children will be assessed for changes on child specific goals using a metric goal attainment assessment method (See Mann, J 2020 Dev Neurorehab). The child will be measured on their percent change on child-specific goals, with ranges from 0 percent change to infinity percent change. The higher the percent change the more the child changed on that particular goal.

    Time frame: 5-12 weeks

07

Study locations

1 site
  • Fralin Biomedical Research Institute at Virginia Tech
    Roanoke, Virginia 24016, United States
08

References and documents

Publications

  • DeLuca SC, Wallace DA, Trucks MR, Mukherjee K. A clinical series using intensive neurorehabilitation to promote functional motor and cognitive skills in three girls with CASK mutation. BMC Res Notes. 2017 Dec 19;10(1):743. doi: 10.1186/s13104-017-3065-z. PubMed 29258560 ↗
  • Mann J, Wallace DA, DeLuca S. Case study on the use of intensive pediatric neurorehabilitation in the treatment of kernicterus. J Clin Mov Disord. 2020 Feb 3;7:1. doi: 10.1186/s40734-020-0084-z. eCollection 2020. PubMed 32042435 ↗
  • Ramey SL, DeLuca S, Stevenson RD, Case-Smith J, Darragh A, Conaway M. Children with Hemiparesis Arm and Movement Project (CHAMP): protocol for a multisite comparative efficacy trial of paediatric constraint-induced movement therapy (CIMT) testing effects of dosage and type of constraint for children with hemiparetic cerebral palsy. BMJ Open. 2019 Jan 15;9(1):e023285. doi: 10.1136/bmjopen-2018-023285. PubMed 30782701 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Dec 2021, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2021
First posted
Mar 25, 2021
StartActual
Apr 30, 2019
Primary completionActual
Dec 30, 2021
CompletionActual
Aug 11, 2022
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04816175
Collaborators
American Academy of Cerebral Palsy and Developmental Medicine
Responsible party
Stephanie DeLuca (Principal Investigator, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Mar 25, 2021
Start date
Apr 30, 2019
Primary completion
Dec 30, 2021
Completion
Aug 11, 2022
Last update
Oct 13, 2022

Study contacts

Stephanie C DeLuca, PhD
principal investigator · Virginia Polytechnic Institute and State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion